Abstract | BACKGROUND: METHODS: RESULTS: As a whole, 82 patients were enrolled. Mean duration of current regimen was 4.6 years and mean duration of plasma HIV RNA < 50 copies/mL before the switch was 46.2 months. Reason for simplification was toxicity in 76 patients and resistance to NRTIs in 13. After switching, the percentage of patients with HIV RNA < 50 copies/mL at week 48 was 92.7% in the intent-to-treat-exposed analysis and 97.6% in the per-protocol analysis. The switch led to a significant reduction in the mean triglyceride value (-85.2 mg/dL), in the prevalence of tubular proteinuria (-56%) and in the mean level of interleukin-6 (-0.94 pg/mL), with a significant increase in the mean phosphoremia (+0.58 mg/dL). Mean trough concentrations of both raltegravir and darunavir were within the therapeutic range. Two patients (2.4%) had virological failure due to suboptimal adherence and 4 subjects (4.9%) discontinued treatment due to adverse events, but no patients experienced Grade 3 or 4 adverse events. CONCLUSION: In our study, simplification to a dual therapy containing raltegravir plus darunavir/ ritonavir after 48 weeks maintained viral suppression in more than 90% of patients and showed a good tolerability with a favourable effect on proteinuria, ipophosphoremia, and lipid metabolism.
|
Authors | Leonardo Calza, Ilaria Danese, Eleonora Magistrelli, Vincenzo Colangeli, Roberto Manfredi, Isabella Bon, Maria Carla Re, Matteo Conti, Pierluigi Viale |
Journal | HIV clinical trials
(HIV Clin Trials)
Vol. 17
Issue 1
Pg. 38-47
(Feb 2016)
ISSN: 1528-4336 [Print] England |
PMID | 26728706
(Publication Type: Journal Article)
|
Chemical References |
- Anti-HIV Agents
- RNA, Viral
- Raltegravir Potassium
- Ritonavir
- Darunavir
|
Topics |
- Adult
- Anti-HIV Agents
(administration & dosage, classification, therapeutic use)
- Darunavir
(administration & dosage, therapeutic use)
- Drug Resistance, Viral
- Female
- Genotype
- HIV Infections
(blood, drug therapy, virology)
- HIV-1
(drug effects, genetics)
- Humans
- Male
- Middle Aged
- RNA, Viral
(blood)
- Raltegravir Potassium
(administration & dosage, therapeutic use)
- Ritonavir
(administration & dosage, therapeutic use)
- Viral Load
|